We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Pathogens and Antibiotic Resistance Detected in Implant/Tissue Infections

By LabMedica International staff writers
Posted on 03 Oct 2012
Scientists from two companies are collaborating to develop a molecular diagnostics solution for detection of pathogens and antibiotic resistance in implant and tissue infections (ITI).

One important application for the platform will be in orthopedics e.g., knee and hip replacement surgeries. More...
A new ITI cartridge, Unyvero, is being developed not only for general surgery, but also for infections caused by biofilms (e.g., on knee and hip implants or catheters), and for abdominal surgery infections, diabetic foot, burn wounds etc.

Curetis AG (Holzgerlingen, Germany) and Heraeus Medical GmbH (Hanau, Germany) signed a collaboration agreement to jointly develop the Unyvero cartridge for the detection of the cause of infections as well as antibiotic resistances of organisms involved in ITI. The resulting Unyvero cartridge and application will be a Curetis-labeled IVD.

The CE-marked Unyvero System is a versatile hardware platform for the detection of a broad panel of bacteria and antibiotic resistances from a single sample in one run. It processes a disposable cartridge providing the necessary reagents to complete the analysis from sample to result.

For development of the new cartridge, the two companies conducted market research in orthopedic applications throughout Europe. They also met with clinicians in Germany, Switzerland, France, the UK, and Scandinavia to determine the pathogens and antibiotic resistances that need to be included in the diagnostic panel of the cartridge.

The partners expect assay development for the new cartridge to be completed by early 2013, with clinical validation and CE marking throughout 2013 and an expected launch in the EU by the end of 2013. The product is will probably include more than 40 and possibly up to 50 analytes.

Currently it takes from 7-15 days to obtain results from biofilm samples. This often leads to prolonged treatment, repeated surgeries and increased morbidity and healthcare costs. Oliver Schacht, CEO of Curetis, said, “We offer highly multiplexed analyte panels of pathogens and resistance markers for applications that require the ability to work with a diverse set of native, complex clinical samples and an unmatched ease of use from sample-to-result in about 4 hours.”

Related Links:

Curetis AG
Heraeus Medical GmbH






Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
New
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Pathology

view channel
image: Researchers Marco Gustav (right) and MD Nic G. Reitsam (left) discuss the study data (Photo courtesy of Anja Stübner/EKFZ)

AI Model Simultaneously Detects Multiple Genetic Colorectal Cancer Markers in Tissue Samples

Colorectal cancer is a complex disease influenced by multiple genetic alterations. Traditionally, studies and diagnostic tools have focused on predicting only one mutation at a time, overlooking the interplay... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.